Tethys Bioscience

Founded in 2005, Tethys creates and commercializes innovative, biomarker-based blood tests that enable healthcare providers to accurately predict imminent disease risk, facilitate targeted intervention and preempt the onset of chronic cardiometabolic conditions. Tethys’ PreDx™ Diabetes Risk Score was developed utilizing proprietary biomarker and algorithm technologies to stratify patients based on disease propensity and to accurately identify those at highest risk of developing type 2 diabetes within five years, thus enabling early interventions clinically proven to prevent or slow progression. Tethys’ breakthrough PreDx platform can improve health outcomes, save lives and reduce the devastating economic impact that debilitating, preventable diseases have on individuals and society.